Adding bil­lions in val­ue, Eli Lil­ly suc­ceeds where Pfiz­er failed, halt­ing breast can­cer re­cur­rence

For years, Eli Lil­ly played strag­gler be­hind Pfiz­er and No­var­tis on a new class of breast can­cer drugs. Now they’ve suc­ceed­ed in a key set­ting where Pfiz­er failed just 3 weeks ago.

In a near­ly 6,000-per­son Phase III tri­al, pa­tients with high risk hor­mone re­cep­tor/HER2 neg­a­tive breast can­cer who were giv­en the Lil­ly drug Verzenio in com­bi­na­tion with en­docrine ther­a­py were sig­nif­i­cant­ly less like­ly to have their can­cer re­cur than pa­tients who were giv­en on­ly en­docrine ther­a­py. Al­though Lil­ly did not re­lease the specifics on the pri­ma­ry end­point, called in­ten­sive dis­ease free sur­vival, these pa­tients nor­mal­ly have a 30% chance of re­cur­rence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.